Celgene to Use Foundation Medicine's Sequencing-Based Test in Cancer Drug Trials
May 17, 2011
Celgene to Use Foundation Medicine's Sequencing-Based Test in Cancer Drug Trials
The goal is to use the test to enable targeted recruitment of patient populations and to stratify patients based on their mutational profile to identify those most likely to respond to Celgene's drug candidates.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Entering NGS Space, Asuragen Launches Cancer Panels Optimized for FFPE on Ion Torrent and GA
January 4, 2012 / Clinical Sequencing News - Foundation Medicine Raises $10M, En Route to Launching Targeted Sequencing Test for Cancer Dx
August 24, 2011 / Clinical Sequencing News - Targeted Sequencing Panels Gaining Ground for Cancer Dx
August 17, 2011 / Clinical Sequencing News - Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
June 8, 2011 / Clinical Sequencing News - Foundation Medicine, MSKCC to Develop Sequencing-based Blood Cancer Test from DNA, RNA
May 8, 2013 / Clinical Sequencing News